Registry update — unassessed
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE) - A Randomized Open-label Intervention of the Fasting-mimicking Diet (FMD) and Rapamycin (NIBBLE)
Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 16, 2026 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- The open-label design (participants knew their group assignment) limits evidence for efficacy, as expectations could influence self-reported outcomes
- No effect sizes or efficacy data are reported, so the magnitude of any benefit or harm is unknown
- Results in APOE4 carriers may not generalize to the broader population, and no long-term outcomes beyond 8 weeks are assessed
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 2 months
- Population
- Middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele
- Primary outcome
- Safety, feasibility, and preliminary efficacy
- Effect size
- —
- Significance
- Not reported
- Journal
- Cedars-Sinai Medical Center
- Published
- Sep 16, 2026
Sources
Primary source
- Cedars-Sinai Medical Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 2. This is not a claim of full-text review.
The study aims to evaluate the safety, feasibility, and preliminary efficacy of the fasting-mimicking diet (FMD) or low-dose daily rapamycin treatment relative to a matched placebo control group when administered over 8 weeks in middle-aged adults at elevated risk for Alzheimer's disease due to the apolipoprotein (APOE) ε4 allele.
Participants randomly assigned to the FMD intervention will adhere to FMD for 5-days over three cycles for a period of approximately 8 weeks. Participants randomly assigned to the rapamycin and placebo groups will take 1 mg of rapamycin or a matched placebo pill daily for approximately 8 weeks.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.